ALKERMES | ALKS - Pre Tax Profit


ALKERMES reported $100.74M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Acadia Pharmaceuticals USD 26.32M 18.28M Dec/2025
ALKERMES USD 100.74M 4.1M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Coherus Biosciences USD -47.4M 14.9M Mar/2025
Eli Lilly USD 7.23B 456M Sep/2025
Gilead Sciences USD 3.64B 1.21B Sep/2025
Heron Therapeutics USD -4.85M 4.39M Sep/2024
Ionis Pharmaceuticals USD -228M 99M Dec/2025
J&J USD 4.97B 2.53B Dec/2025
Merck USD 6.74B 22M Sep/2025
Minerva Neurosciences USD 22.51M 30.74M Sep/2024
Nektar Therapeutics USD -37.05M 15.27M Sep/2024
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Otsuka Holdings JPY 75.26B 91.16B Dec/2025
Pfizer USD 3.33B 290M Sep/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025